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Abstract
Tissue factor (TF) triggers blood coagulation and is translated from two mRNA splice isoforms, encoding membrane-
anchored full-length TF (flTF) and soluble alternatively-spliced TF (asTF). The complete knockout of TF in mice causes
embryonic lethality associated with failure of the yolk sac vasculature. Although asTF plays roles in postnatal angiogenesis, it
is unknown whether it activates coagulation sufficiently or makes previously unrecognized contributions to sustaining
integrity of embryonic yolk sac vessels. Using gene knock-in into the mouse TF locus, homozygous asTF knock-in (asTFKI)
mice, which express murine asTF in the absence of flTF, exhibited embryonic lethality between day 9.5 and 10.5. Day 9.5
homozygous asTFKI embryos expressed asTF protein, but no procoagulant activity was detectable in a plasma clotting
assay. Although the a-smooth-muscle-actin positive mesodermal layer as well as blood islands developed similarly in day 8.5
wild-type or homozygous asTFKI embryos, erythrocytes were progressively lost from disintegrating yolk sac vessels of
asTFKI embryos by day 10.5. These data show that in the absence of flTF, asTF expressed during embryonic development
has no measurable procoagulant activity, does not support embryonic vessel stability by non-coagulant mechanisms, and
fails to maintain a functional vasculature and embryonic survival.
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Introduction
Tissue factor (TF) triggers blood coagulation and supports non-
hemostatic processes through cell signaling. The TF transcript can
undergo alternative splicing of exon 4 to 6, which creates a soluble
protein isoform termed alternatively-spliced TF (asTF) with a
unique C-terminus that lacks the transmembrane and intracellular
domains of full-length TF (flTF) [1]. Although of different lengths,
the C-termini of human and mouse asTF show appreciable
sequence homology within the first 40 amino acids [2].
It is controversial whether asTF exhibits procoagulant activity
[1,3,4,5]. Although asTF lacks important residues that in flTF
interact with macromolecular substrate, the majority of residues
interacting with FVII(a) are present in flTF and asTF [6].
Recombinant murine asTF exhibits minimal, phospholipid-
dependent cofactor activity [2]; nevertheless, procoagulant activity
of murine asTF has not been characterized in in vivo in the
absence of flTF.
TF is crucial for embryonic development, since TF-deficient
embryos fail to sustain a functional yolk sac vasculature and
display embryonic wasting between days 9.5–10.5 [7]. A transgene
expressing human flTF at ,1% of normal murine TF activity is
sufficient to rescue embryonic lethality of knockout mice lacking
murine TF [8] without restoring normal postnatal hemostatic
function [9]. Mice deficient in FV, prothrombin, and protease
activated receptor 1 (PAR1) display a very similar defect in yolk
sac vasculature development and embryonic lethality with a lower
penetrance of 50–60% [10,11,12].
In postnatal angiogenesis, asTF has non-hemostatic roles,
increasing endothelial cell migration and adhesion by signaling
via integrins [13]. It is not known whether the increased lethality
in TF knockout embryos relative to other knockouts of other
factors of the thrombin/PAR1 pathway results from unrecognized
roles of asTF in embryonic vascular development.
In this study, we investigated whether, in the absence of flTF,
expression of asTF during embryonic development yields sufficient
procoagulant activity to improve integrity of yolk sac vasculature
and/or supports vessel stability by non-coagulant mechanisms
[13].
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Methods
Ethics Statement
All animal experiments were approved be the cantonal
veterinary office of Zurich, Switzerland (Protocols 62/2009 and
75/2012).
Generation of asTFKI Mice
Murine asTF open reading frame was obtained by PCR
amplification of mouse aortic mRNA and inserted into KpnI/NotI
restriction sites of a LNTK vector (PolyGene AG, Ruemlang,
Switzerland) located 59 to a Neomycin resistance gene flanked by
two loxP sites (floxed neo). A 3 kb genomic sequence 59 of the first
exon of the TF gene and a 5.2 kb fragment located 39 of the last
exon of the TF gene were used as the left and right homology
arms, respectively. A diphtheria toxin alpha chain minigene (dta)
under control of the DNA polymerase II promoter served as a
negative selection marker; dta was inserted at the 39-end into the
targeting vector. The targeting vector was linearized at its 39-end
prior to electroporation. Embryonic stem cell transfection (129P2/
OlaHsd), screening, cre recombinase-mediated Neomycin exci-
sion, and blastocyst injection were conducted by PolyGene AG
(Ruemlang, Switzerland).
Chimeric mice were bred with C57BL/6J mice for germline
transmission of the mutated allele. The mouse colony was
maintained by breeding of heterozygous animals on a mixed
129P2/OlaHsd-C57BL/6J background. In four heterozygous
asTFKI mice, the open reading frame of the introduced construct
was sequenced and revealed 100% sequence identity with the
murine asTF cDNA transcript (www.ensembl.org: EN-
SMUST00000090417). For embryo analyses, heterozygous
asTFKI mice (F2–F4 generation) were bred and females were
checked for vaginal plugs every morning. The day of the plug was
considered to be E0.5.
Transcript and Protein Expression Analyses
Uteri were dissected at E9.5. Embryos were snap frozen and
yolk sacs were used for genotyping. Total RNA was extracted from
embryos using TRIzol Reagent (Molecular Research Center)
according to the manufacturer’s instructions. 2 mg of RNA was
used to synthesize cDNA using Ready-To-Go You-Prime First-
Strand Beads (GE Healthcare) and random hexamer primers
(TaKaRa). Expression levels of the TF isoforms were measured
using TaqMan expression assays (Applied Biosystems) with a
probe spanning the exon 4 to 5 boundary for flTF
(Mm00438856_m1) and a probe spanning the exon 4 to 6
boundary for asTF (Mm01316952_m1). Eukaryotic 18S rRNA
(4333760T) was used for normalization of expression. Amplifica-
tion efficiencies were measured with serial 10-fold dilutions and
were identical for flTF and asTF. Relative expression levels
represent multiples of ten of 2(Ct[flTF]-Ct[S18]) or 2(Ct[asTF]-Ct[S18]).
Total protein was extracted by manual grinding of the embryos in
a lysis buffer containing 50 mM octylglucoside, 50 mM Tris,
150 mM NaCl, 10 mg/ml aprotinin, and 10 mg/ml leupeptin
pH 7.4. Lysates were precipitated with 220uC acetone overnight
and resuspended in non-reducing sample buffer with careful
sonication. Samples were separated by 10% SDS-PAGE and
transferred to a PVDF membrane (Immobilion-FL, Millipore).
The membrane was stained with polyclonal rabbit anti-mouse TF
antibody (R8084) [14], polyclonal rabbit anti-mouse asTF
antibody [2], and anti-human GAPDH (cross-reactive to mouse)
mouse monoclonal (MAB374, Millipore) primary antibodies,
followed by staining with goat anti-rabbit 800CW and donkey
anti-mouse 680 LT (LI-COR Biosciences) secondary antibodies.
Staining was visualized on an Odyssey imager and quantified
using the corresponding application software (version 3.0; both LI-
COR Biosciences).
TF Activity Assay
Procoagulant activity was determined in whole embryos using a
plasma clotting assay [15]. Uteri were dissected at E9.5, embryos
were snap frozen, and yolk sacs were used for genotyping.
Embryos were lysed by manual grinding in HEPES-saline
containing 0.02% sodium azide (HBS) After total protein
quantification with a Bradford assay (Bio-Rad), embryo lysates
were diluted in HBS containing 1 mg/ml BSA and 50 mM
phospholipid vesicles (70% phosphatidylcholine (PC) and 30%
phosphatidylserine (PS), Avanti polar lipids) to measure TF activity
using a plasma clotting assay. Human and mouse citrated plasma
was mixed 9:1 (50 ml) in order to provide mouse factor VII for
optimal mouse TF procoagulant activity and prewarmed together
with the sample (50 ml) or a reference (recombinant lipidated
human TF, American Diagnostica). Clotting times were measured
after addition of 25 mM CaCl2 (50 ml). Procoagulant activities
were calculated using a standard curve prepared with serial
dilutions of recombinant human TF and normalized to the total
protein concentration of the sample.
Figure 1. Targeting of the TF gene. The murine TF allele was targeted with a replacement-type vector containing the murine asTF open reading
frame flanked by 3 kb 59 and 5.2 kb 39 homology arms. Diphtheria toxin (dt) was used for negative selection. After homologous recombination into
129P2/OlaHsd embryonic stem cells, a loxP flanked neomycin resistance cassette was removed by transfection with a Cre expression plasmid.
doi:10.1371/journal.pone.0097793.g001
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Embryo Preparation for Histology
At E8.5, 9.5, or 10.5, uteri were fixed with 4% formalin in PBS
for at least 4 days. Using a razor blade, individual implantation
sites were separated and each implantation site was halved
transversely to the uterus walls. From one half, a piece of
embryonic tissue was taken and washed with PBS before
genotyping followed by dissection of the yolk sac for en face
evaluation. The other half was embedded in paraffin and
sectioned to perform H&E or immunohistochemical staining of
smooth muscle a-actin (Sigma, F3777). The primary FITC labeled
mouse anti a-SMA antibody was detected with a rabbit anti-FITC
antibody. The latter was detected with a biotinylated anti-rabbit
antibody marked with a HRP labeled streptavidin-biotin-complex.
The diaminobenzidine chromogen developed brown color reac-
tion. Immunohistochemical staining using the anti-mouse asTF
polyclonal antibody or rabbit IgG isotype control (Jackson
Immunoresearch) was performed as described [2].
Yolk sac erythrocytes or a-SMA+-cells were counted manually
and normalized to the cross-sectional length of the yolk sac which
was determined using the AnalySIS FIVE software (Quality
Report).
Statistical Analysis
Data are shown as mean 6 SEM. x2 analysis was used to
compare genotype distributions. Unpaired Student’s t-test was
performed for comparison of two groups, one-way ANOVA with
Bonferroni posttest was used to compare three groups and two-
way ANOVA with Bonferroni posttest was used to compare
genotypes at different timepoints. p values,0.05 were considered
significant.
Results
Generation of asTF Knock-in Mice
To study the function of asTF in the absence of flTF in vivo, an
asTF knock-in (asTFKI) mouse was generated by replacing the TF
gene with the murine asTF coding sequence under the control of
the murine TF(F3) promoter (Fig. 1A). This novel genetic model
enabled investigation of asTF function in the physiological setting
of embryonic development.
Homozygous asTFKI Embryos Die after Day E9.5
We genotyped 148 offspring from 3 different heterozygous
asTFKI/wtTF breeding pairs and found no homozygous asTFKI,
106 heterozygous asTFKI/wtTF (72%), and 42 (28%) wt animals
(Fig. 2). Deletion of the TF gene in mice leads to embryonic
lethality between embryonic day 9.5 and 10.5 [7]. To determine
whether homozygous asTFKI embryos develop to this stage, 48
E9.5 embryos were genotyped. 13 homozygous asTFKI (27%), 25
heterozygous asTFKI/wtTF (52%), and 10 wt (21%) embryos
were identified, demonstrating normal Mendelian segregation
significantly different from the genotype distribution found at birth
(p = 0.0001) (Fig. 2). Thus, asTFKI embryos die during develop-
ment after day 9.5.
Expression of TF Splice Isoforms in E9.5 Embryos
Wt embryos expressed both flTF and asTF mRNA. The mRNA
expression of flTF decreased by 52% in heterozygous asTFKI/
wtTF embryos (p,0.01) and was undetectable in homozygous
asTFKI embryos (p,0.001 vs. wt). mRNA expression of asTF was
3-fold higher in heterozygous asTFKI/wtTF (p.0.05) and 5.9-
fold higher in homozygous asTFKI embryos (p,0.01) relative to
wt embryos, which is a magnitude of expression expected from the
switch to a single splice variant expressed by one or two alleles,
respectively (Fig. 3A). Using an antibody reactive with both forms
of murine TF [14], we observed partial overlap of flTF and asTF
bands on western blots (Fig. 3B). Homozygous asTFKI embryos
displayed expression of a more homogenous TF protein, with a
predominant higher apparent molecular weight species also seen
in wt and heterozygous asTFKI/wtTF embryos. Since three
extracellular N-linked glycosylation sites of flTF are preserved in
asTF, the observed apparent molecular weights of the splice
isoforms most likely result from size differences in the protein as
well as carbohydrate structures [2]. Quantification of TF protein
levels revealed that homozygous asTFKI embryos expressed 19%
of total TF detected in wt embryos, whereas heterozygous embryos
expressed 76% of wt levels. Western blotting using an antibody
selectively reactive with murine asTF [2] showed comparable
expression of asTF in homozygous asTFKI, heterozygous
asTFKI/wtTF, and wt embryos, indicating that the introduced
asTFKI allele did not cause a major overexpression relative to
endogenous asTF. Immunohistochemical staining using the anti-
mouse asTF antibody [2] confirmed, in a semi-quantitative
manner, comparable expression of asTF in embryonic (heart)
and extraembryonic (yolk sac) tissues in homozygous asTFKI and
wt embryos, and throughout E8.5 to E10.5 (Fig. 3C).
Defective Yolk Sac Vasculature in Homozygous asTFKI
Embryos
In order to address the question whether asTF supported
thrombin generation sufficiently to maintain integrity of the yolk
sac vasculature, we analyzed procoagulant activity in whole E9.5
embryo lysates in a plasma clotting assay. Procoagulant activity of
wt embryos was equivalent to 758635 pmol recombinant TF/g of
total protein. In contrast, asTFKI embryo extracts showed .5
orders of magnitude lower procoagulant activity (p,0.001)
(Fig. 3D) and did not shorten clotting times relative to buffer
control. Thus, murine asTF expressed in vivo in the absence of
flTF lacked measurable procoagulant activity.
We asked whether asTF supported vessel stability via non-
coagulant mechanisms by analyzing yolk sac histology from days
Figure 2. Genotype distribution on E9.5 and birth. Homozygous
asTFKI embryos die after developmental day E9.5. Genotype distribu-
tion of offspring from heterozygous breeding pairs at birth (black bars)
differs from that at embryonic day 9.5 (grey bars). At day 9.5, embryonic
genotypes are distributed in a Mendelian manner, while no more
homozygous asTFKI pups can be identified at birth (p = 0.0001, x2-test).
doi:10.1371/journal.pone.0097793.g002
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E8.5 to E10.5. In homozygous asTFKI mice, early yolk sac vessels
developed normally up to day E8.5, were filled with nucleated
embryonic erythrocytes, and stained for a-smooth-muscle-actin (a-
SMA) in the mesodermal layer, as seen in wt vessels (Fig. 4A). On
day 9.5, homozygous asTFKI embryos showed various stages of
growth retardation and wasting. Erythrocyte number was reduced
Figure 3. Expression and activity of asTF. (A) RNA levels of asTF and flTF were measured in E9.5 whole embryos and normalized to S18
expression, N = 5–7, ***P,0.001, **P,0.01 (B) Protein expression of total TF (western blot probed with a rabbit anti-mouse TF polyclonal antibody),
asTF (western blot probed with a rabbit anti-mouse asTF polyclonal antibody), and GAPDH in E9.5 whole embryos. Intensity of normalized total TF
staining relative to wt (100%) was 74% in asTFKI/wtTF embryos and 19% in asTFKI/asTFKI embryos. Expression of asTF was comparable between
homozygous asTFKI, heterozygous asTFKI/wtTF and wt embryos (C) Mouse asTF and rabbit IgG control immunohistochemistry on E9.5 homozygous
asTFKI and E10.5 wt yolk sac. Mouse asTF immunohistochemistry on E8.5 to E10.5 extraembryonic (yolk sac) and embryonic (heart) tissue of
homozygous asTFKI and wt embryos. (D) TF activity of whole embryo lysates was measured with a plasma clotting assay and normalized to total
protein. N= 5, ***P,0.001.
doi:10.1371/journal.pone.0097793.g003
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Figure 4. Yolk sac histology. (A) On day E8.5, Haematoxylin and Eosin (H&E) staining and a-SMA immunohistochemistry show comparable
integrity, erythrocyte filling, a-SMA staining of the mesodermal layer of homozygous asTFKI and wt yolk sacs. (B) On day E9.5, erythrocyte content,
wall thickness, and number of a-SMA expressing cells are reduced in homozygous asTFKI yolk sacs. AsTFKI embryos are found at different stages of
growth retardation and wasting. (C) On day E10.5, depletion of erythrocytes, reduced number of a-SMA+ cells, thinning and detachment of
Alternatively Spliced Tissue Factor in Development
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(p,0.001); walls of homozygous asTFKI yolk sac vessels appeared
thinner, and number of a-SMA expressing cells tended to be
reduced (p.0.05, ANOVA; p= 0.07, t-test) compared to yolk sac
vessels from wt embryos (Fig. 4B and D). On day 10.5, all
homozygous asTFKI embryos were dead and their yolk sac vessels
lacked erythrocytes (p,0.01). While yolk sacs of wt embryos had
developed large vitelline vessels with high number of a-SMA+-
cells, homozygous asTFKI yolk sacs displayed thin walled
capillaries with low number of a-SMA expressing cells (p,0.01)
and partial separation of mesodermal from endodermal layer. En
face preparation clearly showed the absence of blood-filled yolk
sac vessels in homozygous asTFKI mice (Fig. 4C).
Discussion
Lethality of TF deficient embryos is associated with a failure to
sustain functional yolk sac vasculature [7,16,17]. A similar
phenotype of the yolk sac vasculature was observed when other
clotting factors (FV, prothrombin, and thrombin receptor PAR1)
were knocked out, but penetrance and lethality was only 50–60%
in the latter [10,11,12]. In contrast, deficiency in PAR2, which is
activated by the TF/FVIIa complex, did not result in yolk sac
abnormalities [18]. In mouse models, human flTF protein levels as
low as 1% were sufficient to rescue yolk sac vessel development
and preserve survival [8]. Hence, thrombin generation and PAR1
signaling, but not PAR2 signaling, are crucial, but this pathway is
not necessarily the only contributor by which TF provides yolk sac
vessel integrity.
Additional non-hemostatic effects of both flTF and asTF have
been described in tumor angiogenesis [13,19,20,21]. While flTF
induces endothelial cell migration via PAR2 [22], asTF acts
through direct binding to endothelial integrins [13]. Although
vasculogenesis in the early yolk sac is initiated by mesodermal
precursor cells forming the primary capillary plexus, migration
and differentiation of pericytes/smooth muscles cells is required
for stabilization and maturation of the vessels similar to postnatal
angiogenesis [23,24]. The loss of vascular integrity in TF deficient
yolk sacs has been attributed to paucity of pericytes [7]. However,
it was not known whether asTF might stabilize yolk sac vessels and
thus partially rescue total TF deficiency, leading to reduced, 50–
60% lethality as seen in knockouts of the thrombin/PAR-1
pathway.
With the newly generated asTFKI mice that express asTF
under the control of the endogenous TF promoter, we provide
answers to these questions. RNA expression of asTF was 5.9-fold
higher in homozygous asTFKI embryos compared to wt embryos,
which is consistent with a switch from an allele coding for two
splice variants to an allele coding for a single splice variant. The
increase in asTF RNA in asTFKI embryos did, however, not fully
translate into increased asTF protein expression but yielded asTF
protein levels comparable to those of wt embryos. Translation of
asTF mRNA in asTFKI embryos might be influenced by the lack
of introns in the asTFKI construct, since splicing factors regulate
nuclear export and translation of mRNA [25,26]. AsTF protein
expression was analysed using a polyclonal anti-mouse TF
antibody [14] and a polyclonal anti-mouse asTF antibody [2].
Both antibodies detected a protein of the same electrophoretic
mobility in homozygous asTFKI embryos, which strongly suggests
– but does not unequivocally prove – expression of asTF protein.
Quantity of material and sensitivity of the antibodies are a
limitation in the analysis of asTF protein expression in this study.
Homozygous asTFKI embryos died on day 9.5–10.5. They
exhibited yolk sac phenotype similar to the one observed in TF
deficient mice [7] with failure of the yolk sac vasculature. Although
asTF was expressed at physiologic levels in E9.5 homozygous
asTFKI embryos, no pro-coagulant activity could be detected in a
sensitive clotting assay. Thus, asTF has no appreciable procoag-
ulant activity in the absence of flTF during embryonic develop-
ment in vivo. Furthermore, histological analyses suggest that non-
hemostatic properties of asTF are insufficient to stabilize yolk sac
vessels and assure vascular integrity. Consistently, asTF did not
affect pericyte migration, although it increased endothelial cell
migration 4–10 fold [13]. Tumors formed by asTF overexpressing
flTF-null cells not only displayed high vascularization, but also
abundant vascular leakage, further indicating insufficient vessel
maturation [20]; on the other hand, asTF potentiated develop-
ment of functional vessels in vivo when overexpressed in flTF-
positive pancreatic cancer cells [27]. These data support the
emerging concept that integrin-mediated signaling exerted by
asTF, and coagulation-protease signaling by flTF play distinct and
non-overlapping roles in post-natal and developmental angiogen-
esis.
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